NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/08/2026 10:52
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization262.22 mln
Float102 mln
Earnings Date08/05/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-4.17
Highly reliable
1-Year Forecast
5.44
Transformational upside
Relative Strength
99
/ 100
Top performer
Debt / Equity
0.38
Low leverage
ROE
-52.04
Deeply negative
Business Description
Fate Therapeutics is a San Diego-based clinical-stage biotech company focused on developing next-generation cell-based treatments for cancer and immune system disorders. Its pipeline includes several NK and T-cell therapies engineered to target specific diseases, ranging from blood cancers like B-cell lymphoma to complex autoimmune conditions such as lupus. The company works with Ono Pharmaceutical under a collaboration agreement to advance off-the-shelf cell therapies for solid tumors. Founded in 2007, Fate Therapeutics operates both in the United States and in international markets.
